Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000114 Eli Lilly and Company 03/31/2022 00002473230 Olumiant Package Size: 30 Strength: 1 mg Dosage Form: TABLET 01/01/2022 118.80 2497.20 06/08/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Olumiant and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Olumiant. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002418230 Olumiant Package Size: 30 Strength: 2 mg Dosage Form: TABLET 01/01/2022 118.80 2497.20 06/08/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Olumiant and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Olumiant. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002144511 Taltz Package Size: 1 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR 01/01/2022 298.40 6272.80 02/04/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002772411 Taltz Package Size: 1 Strength: 80 mg/mL Dosage Form: SYRINGE 01/01/2022 298.40 6272.80 02/04/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002144527 Taltz Package Size: 2 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR 01/01/2022 596.80 12545.60 02/04/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002144509 Taltz Package Size: 3 Strength: 80 mg/mL Dosage Form: AUTO-INJECTOR 01/01/2022 895.20 18818.40 02/04/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Taltz and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Taltz. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002143380 Trulicity Package Size: 4 Strength: 0.75 mg/0.5 mL Dosage Form: PEN INJECTOR 01/01/2022 42.20 886.56 12/07/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Trulicity and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Trulicity. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002143480 Trulicity Package Size: 4 Strength: 1.5 mg/0.5 mL Dosage Form: PEN INJECTOR 01/01/2022 42.20 886.56 12/07/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Trulicity and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Trulicity. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002481554 Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET 01/10/2022 179.48 3444.00 12/15/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002533754 Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET 01/10/2022 179.48 3444.00 12/15/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002621654 Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET 01/10/2022 179.48 3444.00 12/15/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114 Eli Lilly and Company 03/31/2022 00002448354 Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET 01/10/2022 179.48 3444.00 12/15/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering Verzenio and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of Verzenio. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000079 EMD Serono, Inc. 03/31/2022 44087122501 Cetrotide® (cetrorelix acetate for injection) Subcutaneous Kit 0.25 MG 01/25/2022 16.32 267.35 07/12/2021 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087907001 Gonal-f® Multi-Dose (follitropin alfa for injection) Injection Solution Reconstituted 1050 UNIT 01/25/2022 192.39 3152.57 08/23/2019 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087903001 Gonal-f® Multi-Dose (follitropin alfa for injection) Injection Solution Reconstituted 450 UNIT 01/25/2022 82.45 1351.10 08/23/2019 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087900501 Gonal-f® RFF* (follitropin alfa for injection) Subcutaneous Solution Reconstituted 75 UNIT -01 *Revised Formulation Female 01/25/2022 13.74 225.18 06/16/2015 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087900506 Gonal-f® RFF* (follitropin alfa for injection) Subcutaneous Solution Reconstituted 75 UNIT -10 *Revised Formulation Female 01/25/2022 137.42 2251.84 06/16/2015 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087111501 Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 300 UNIT/0.5ML *Revised Formulation Female 01/25/2022 54.96 900.73 04/02/2024 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087111601 Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 450 UNT/0.75ML *Revised Formulation Female 01/25/2022 82.45 1351.10 04/02/2024 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087111701 Gonal-f® RFF* Redi-ject™ (follitropin alfa for injection) Rediject Subcutaneous Solution Pen-injector 900 UNIT/1.5ML *Revised Formulation Female 01/25/2022 164.90 2702.20 04/02/2024 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400000 Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 5174.60 91418.90 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400004 Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 2069.84 36567.56 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400005 Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 2587.30 45709.45 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400006 Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 3104.76 54851.34 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400007 Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 3622.22 63993.23 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400008 Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 4139.68 73135.12 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 06/30/2022 44087400009 Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG 04/06/2022 4657.14 82277.01 10/16/2026 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 03/31/2022 44087115001 Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Subcutaneous Injectable 250 MCG/0.5ML 01/25/2022 12.40 203.20 03/16/2021 Single Source Drug None 1 The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. None None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 09/30/2022 44087000407 Serostim Subcutaneous Solution Reconstituted 4 MG, 7 vials 07/06/2022 176.68 3119.48 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 09/30/2022 44087000507 Serostim Subcutaneous Solution Reconstituted 5 MG, 7 vials 07/06/2022 220.85 3899.35 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000079 EMD Serono, Inc. 09/30/2022 44087000607 Serostim Subcutaneous Solution Reconstituted 6 MG, 7 vials 07/06/2022 265.02 4679.22 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2022 67979051143 AVEED, 750 mg/3mL (250mg/1mL) solution, single use vial 04/01/2022 72.05 1557.60 05/08/2027 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2022 67979051143 Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial 11/21/2022 76.32 1633.92 05/08/2027 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/19/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244001002 Edex®, Alprostadil For Inj Kit 10 MCG, 2 01/01/2022 8.10 151.76 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244001006 Edex®, Alprostadil For Inj Kit 10 MCG, 6 01/01/2022 24.32 455.34 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244002002 Edex®, Alprostadil For Inj Kit 20 MCG, 2 01/01/2022 10.47 196.06 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244002006 Edex®, Alprostadil For Inj Kit 20 MCG, 6 01/01/2022 31.41 588.14 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244004002 Edex®, Alprostadil For Inj Kit 40 MCG, 2 01/01/2022 14.30 267.73 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244004006 Edex®, Alprostadil For Inj Kit 40 MCG, 6 01/01/2022 42.89 803.15 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481002509 FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 01/01/2022 87.08 1062.41 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481068706 LIDODERM®, Lidocaine Patch 5%, 30 01/01/2022 59.31 723.57 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481062970 PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 01/01/2022 254.82 3108.79 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481062770 PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 01/01/2022 128.88 1572.36 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481062370 PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 01/01/2022 180.38 2200.64 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481062385 PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 01/01/2022 879.21 10726.38 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 63481062870 PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 01/01/2022 194.88 2377.50 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2022 67979000201 SUPPRELIN LA, 50 mg implant, ea 04/01/2022 2110.37 45179.19 06/16/2026 Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/20/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244010010 THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 01/01/2022 23.89 291.49 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244020010 THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 01/01/2022 35.51 433.21 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244030010 THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 01/01/2022 43.64 532.45 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 03/31/2022 52244040010 THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 01/01/2022 61.41 749.23 None Non-innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/21/2022. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2022 67979000101 VALSTAR, 40 mg/1ml solution, 4x5mL 04/01/2022 356.33 7703.43 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/20/2022, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2022 67979000101 Valstar, 40 mg/1ml solution, 4x5mL 10/01/2022 373.62 8077.05 None Innovator Multiple Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/19/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 06/30/2022 66887000301 XIAFLEX, 0.9mg powder for solution, single use vial 04/01/2022 212.08 5650.09 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091 Endo Pharmaceuticals Inc. 12/31/2022 66887000301 Xiaflex, 0.9mg powder for solution, single use vial 10/01/2022 220.35 5870.44 None Single Source Drug None 1 None 1 The price increase was not necessitated by a change or improvement in the drug. None None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000405 Esperion 03/31/2022 72426011803 Nexletol 30 Tab 180 mg/1 Tablet Film Coated 01/01/2022 34.63 384.43 12/03/2025 Single Source Drug 149200 None Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. None None 1 None None None None None None None None None None None
Rx0000405 Esperion 03/31/2022 72426081803 Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated 01/01/2022 34.63 384.43 03/14/2036 Single Source Drug 156754 None Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. None None 1 None None None None None None None None None None None
Rx0000104 EUSA Pharma (US) LLC 12/31/2022 73090042001 SYLVANT 100 mg vial 10/01/2022 57.12 1326.51 09/13/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000104 EUSA Pharma (US) LLC 12/31/2022 73090042101 SYLVANT 400 mg vial 10/01/2022 228.48 5306.04 09/13/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000104 EUSA Pharma (US) LLC 06/30/2022 73090042001 Sylvant Intravenous Solution Reconstituted 100 MG 04/01/2022 33.50 1269.39 09/13/2027 Single Source Drug None 1 None 1 None 1 12/22/2018 Janssen Biotech 115000000 None Acquisition price is for both NDCs 910.24 883.73 2014 833.00 None None
Rx0000104 EUSA Pharma (US) LLC 06/30/2022 73090042101 Sylvant Intravenous Solution Reconstituted 400 MG 04/01/2022 134.01 5077.56 09/13/2027 Single Source Drug None 1 None 1 None 1 12/22/2018 Janssen Biotech 115000000 None Acquisition price is for both NDCs 3640.96 3534.92 2014 3332.00 None None
Rx0000455 Evofem Biosciences, Inc. 12/31/2022 69751010012 Phexxi Vaginal Gel 1.8-1-0.4%, 5 GM, Unit-of-Use, Box Qty 12 10/01/2022 44.10 338.10 03/15/2033 Single Source Drug 142452 None Evofem has experienced unexpectedly high rebate demands from PBMs combined with high demand for patient assistance programs. We had anticipated Phexxi coverage to be improved by the ACA Preventive Services regulations. However most PBMs are not recognizing Phexxi as a preventive contraceptive product. None None None None None None None None None None None None None None